# Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery

> **NCT00513266** · PHASE2 · UNKNOWN · sponsor: **Centre Hospitalier Universitaire Vaudois** · enrollment: 35 (estimated)

## Conditions studied

- Colorectal Cancer
- Metastatic Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **BIOLOGICAL:** cetuximab
- **DRUG:** fluorouracil
- **DRUG:** irinotecan hydrochloride
- **DRUG:** leucovorin calcium
- **DRUG:** oxaliplatin
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** adjuvant therapy
- **PROCEDURE:** biopsy
- **PROCEDURE:** conventional surgery
- **PROCEDURE:** neoadjuvant therapy

## Key facts

- **NCT ID:** NCT00513266
- **Lead sponsor:** Centre Hospitalier Universitaire Vaudois
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2009-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00513266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00513266, "Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00513266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*